Prostate lesion tissue immunofluorescence detection kit and detection method
By adopting abiotic amplification system and multiple rounds of labeling technology in the prostate lesion tissue immunofluorescence detection kit, the problems of antibody species limitation and long experimental cycle in the existing technology are solved, and rapid and strong signal multiple labeling detection is achieved, which is suitable for the diagnosis of lesions such as prostate cancer.
Patent Information
- Application Number
- CN202411884716.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-20
- Publication Date
- 2025-03-21
- Estimated Expiration
- 2044-12-20
AI Technical Summary
During the detection of the existing immunohistochemistry double staining kit for prostate lesions, the use of ready-to-use combination antibodies, resulting in different types of antibodies. Rabbit monoclonal antibodies with strong specificity and strong affinity cannot be used at the same time, and it is easy to cause circulating staining, and the experimental cycle is long.
Using abiotic amplification system, combined with TYR-xxxPlus fluorescent dye and TSA Buffer, HRP-labeled secondary antibodies catalyze the activation of tyramine fluorescein substrate in the presence of hydrogen peroxide, to achieve fluorescent signal amplification, and triple labeling is achieved through multiple rounds of labeling technology to avoid interference from endogenous biotin.
It greatly shortens the experimental time, enhances the intensity of fluorescence signal, avoids circulating staining and endogenous biotin interference, and is suitable for the diagnosis and differential diagnosis of prostate cancer, PIN, and AAH.